Systemic adjuvant therapies for early breast cancer: 15-year results for recurrence and survival

John F Forbes and Jack Cuzick
Med J Aust 2005; 183 (9): . || doi: 10.5694/j.1326-5377.2005.tb07120.x
Published online: 7 November 2005

There is clear evidence of long-term benefits

The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 2000 overview of adjuvant systemic treatment trials for early breast cancer has demonstrated clear evidence of substantial and significant reductions in both recurrence and mortality, with follow-up now to 15 years.1 This is the fourth EBCTCG overview of adjuvant systemic therapies, conducted at 5-year intervals since 1985.2-6 The EBCTCG 2000 analysis, based on individual patient data from 145 000 women diagnosed with early breast cancer, involved 194 trials started by 1995 in which chemotherapy and hormonal therapy were evaluated alone and in combination for their effects on recurrence, breast cancer mortality and total mortality. This overview, with data from more trials than the earlier overviews, more patients and more years of follow-up, provided new and long-term information on adjuvant chemotherapy in women aged 50–69 years, tamoxifen duration, combined modality therapy, and cause-specific mortality (Box).

  • John F Forbes1
  • Jack Cuzick2

  • 1 Department of Surgical Oncology, Newcastle Mater Hospital, University of Newcastle, Waratah, NSW.
  • 2 Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, London, UK.


Competing interests:

Professor John Forbes and Professor Jack Cuzick are Early Breast Cancer Trialists’ Collaborative Group collaborators.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.